Hyoscyamine sulfate hydrate

Suppliers

Names

[ CAS No. ]:
620-61-1

[ Name ]:
Hyoscyamine sulfate hydrate

[Synonym ]:
Benzeneacetic acid, α-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, sulfate, hydrate (2:1:1) (salt)
Atropina Solfato
UNII:03J5ZE7KA5
L-TROPINE TROPATE SULFATE
atropine sulphate
L-Hyoscyamine Hemisulfate
atropin sulfate
Benzeneacetic acid, α-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (αS)-, sulfate (2:1) (salt)
(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate hydrate (2:1:1)
Atropine Sulfate Monohydrate
MFCD00078244
(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate (2:1) hydrate (salt)
levsinsulfate
EINECS 210-644-6
Atropinsulfat
(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate sulfate (2:1)
L-HYOSCYAMINE SULFATE
Hyoscyamine sulfate hydrate

Chemical & Physical Properties

[ Melting Point ]:
205-206ºC

[ Molecular Formula ]:
C17H24NO5S0.5

[ Molecular Weight ]:
676.817

[ Exact Mass ]:
676.302979

[ PSA ]:
191.75000

[ LogP ]:
4.10130

[ Index of Refraction ]:
-28 ° (C=5, H2O)

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
YM6107000
CAS REGISTRY NUMBER :
620-61-1
LAST UPDATED :
199712
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C34-H46-N2-O6.H2-O4-S
MOLECULAR WEIGHT :
676.90

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
400 uL/kg/1D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Cardiac - pulse rate increase, without fall in BP Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 15,532,1997
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
800 uL/kg/1D-I
TOXIC EFFECTS :
Behavioral - irritability Cardiac - pulse rate increase, without fall in BP Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 15,532,1997
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
400 uL/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate increase, without fall in BP Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 15,532,1997
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
210 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 55,849,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80431 No. of Facilities: 967 (estimated) No. of Industries: 3 No. of Occupations: 9 No. of Employees: 3990 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80431 No. of Facilities: 445 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 14970 (estimated) No. of Female Employees: 12609 (estimated)

Safety Information

[ Risk Phrases ]:
R26/28

[ Safety Phrases ]:
S1;S45;S24/25

[ RTECS ]:
YM6107000


Related Compounds

  • Hyoscyamine Sulfate
  • HYOSCYAMINE SULFATE
  • Uranyl sulfate hydrate
  • zinc sulfate hydrate
  • Lutetium sulfate hydrate (2:3:1)
  • CYSTAMINE SULFATE HYDRATE 98
  • 3-chloro-N-(2-{[(4,6-dimethylpyrimidin-2-yl)sulfanyl]methyl}-1-methyl-1H-benzimidazol-5-yl)-4-fluorobenzamide
  • C25H23N7O2S
  • N-[3-(1,3-dihydro-2H-benzimidazol-2-ylideneamino)-3-oxopropyl]-5,6,7-trimethoxy-1-methyl-1H-indole-2-carboxamide
  • C19H16ClN5O3S2
  • 6-chloro-N~2~-(4-methyl-1,3-thiazol-2-yl)imidazo[1,2-a]pyridine-2-carboxamide
  • 6-{4-[(2,5-dichlorophenyl)sulfonyl]piperazin-1-yl}-9H-purine
  • Methyl 4-Oxo-4-[4-[4-(phenethylcarbamoyl)phenoxy]-1-piperidyl]butanoate
  • 1-[1-(4-fluorophenyl)-3-methyl-6-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1,4-diazepane
  • 3-[1-(4-Bromobenzoyl)piperidin-4-yl]-4-methylisoxazol-5-amine
  • N-[2-(3-chlorophenyl)-1,3-benzoxazol-5-yl]butanamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.